Получение гендерно-подтверждающей терапии vs. жизнь без медицинского лечения
Если вы действуете
Пройти гендерно-аффирмативное лечение
3,0%
Если вы бездействуете
Жить без гендерно-аффирмативного лечения
Прямого измерения нет
Хотя бы одно число является косвенной оценкой, а не измеренной долей сожалеющих. Как получено каждое число, описано ниже.
Здоровье
Последнее обновление 2026-05-04
Качество доказательств 4.5/5
Оценка по восьми измерениям согласно
рубрике качества
. Каждое измерение оценивается от 1 до 5.
D1 Проверка источников
4/5
D2 Авторитетность и независимость источника
5/5
D3 Точность уровня сожаления
3/5
D4 Сопоставимость источников
4/5
D5 Шаблон Гиловича
5/5
D6 Качество текста
5/5
D7 Полнота оговорок
5/5
D8 Качество выборки
5/5
Среднее4.5/5
Косвенные данные: по этому решению хотя бы один показатель получен из косвенной меры, такой как последствия, удовлетворённость или намерение, либо из редакционной оценки, а не из прямого опроса о сожалении. В примечаниях к каждой стороне ниже описано, как получен показатель.
Если вы действуете
Пройти гендерно-аффирмативное лечение
3,0%
~2–4% получивших гендерно-аффирмативную хирургию сообщают о сожалении; доли сожаления только для гормонов ниже
Трансгендерные и небинарные взрослые, получившие гендерно-аффирмативную медицинскую помощь (Expósito-Campos 2021, систематический обзор; WPATH SOC v8, обзор доказательств)
наблюдение после лечения (различное, 1–30 лет)
Если вы бездействуете
Жить без гендерно-аффирмативного лечения
Прямого измерения нет
Ни один источник не приводит число для этой стороны, поэтому мы его не показываем.
Трансгендерные и гендерно-разнообразные взрослые без доступа к гендерно-аффирмативной помощи или отложившие её (US Transgender Survey 2022; Turban et al. 2020)
поперечно и ретроспективно; взрослый возраст
Число для каждого выбора (что именно измерено, указано на странице)
Пройти гендерно-аффирмативное лечениеЖить без гендерно-аффирмативного лечения
3,0%Прямого измерения нет
Похожие решения
Семантически близкие решения — та же область, другие компромиссы.
Число для каждого выбора (что именно измерено, указано на странице)
Отказаться от конвенционального лечения рака; использовать исключительно альтернативную медицину (без операции, химиотерапии, лучевой или гормональной терапии)Принять конвенциональное лечение рака (операция, химиотерапия, лучевая, гормональная терапия согласно стадии)
No survey directly measures the regret of adults who want gender-affirming care and live without it, so this side has no direct measurement, which is why this entry is flagged as proxy-only. The evidence is indirect. Turban et al.’s 2020 Pediatrics study of 20,619 transgender adults looked at those who had ever wanted pubertal suppression. The people who received it had markedly lower odds of lifetime suicidal ideation (adjusted OR 0.3) than those who wanted it but could not access it. The 2022 U.S. Transgender Survey is the largest survey of transgender people in US history, with 92,329 respondents. Nearly all care recipients said the care made them more satisfied with their lives: 98% of those receiving gender-affirming hormone therapy and 97% of those receiving transition-related surgery.
Bustos et al.’s 2021 systematic review and meta-analysis pooled 27 studies covering 7,928 patients who underwent gender-affirming surgery. The pooled regret prevalence was 1% (95% CI <1%–2%). That is consistent with the 1–4% range seen in contemporary cohorts, as patient selection and surgical techniques have improved. Regret after hormonal treatment alone is lower than after surgery. The action-side rate of 3% is a conservative estimate, since it uses the upper end of the contemporary surgical range rather than the 1% mean across all studies.
The clinical evidence on outcomes is now extensive and consistent. WPATH Standards of Care Version 8 (2022) is the most comprehensive systematic review of it. It confirms that gender-affirming medical and surgical interventions are associated with significant reductions in gender dysphoria, depression, anxiety and suicidality in transgender and gender diverse adults. Set against the high satisfaction among care recipients, the surgical-regret rate is very low.
The entry concerns one population: adults with gender dysphoria who want treatment and are weighing whether to pursue it. For them the evidence consistently shows rare regret after care. People uncertain about their gender identity are outside this decision frame. Their question is different, and the evidence base for it is sparser. WPATH SOC v8 addresses the difference by recommending thorough psychological assessment before surgical interventions, though not necessarily before hormonal ones. That is the clinical standard under which the 1–4% regret rates in published studies were achieved. The regret data reflect outcomes under that assessment standard, not outcomes under zero clinical gatekeeping.
Источники: действие
Реестр утверждений
Каждое число ниже — это то, что сообщил источник, с дословной цитатой, на которую мы опирались, и тем, как мы пришли к нашей цифре. Нажмите на ссылку, чтобы проверить самостоятельно.
1/2 источников независимо дословно сверены с указанным источником
[1]International Journal of Transgender Health / WPATH — Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Рецензируемая публикация
Systematic evidence review confirms gender-affirming care significantly reduces gender dysphoria, depression, anxiety, and suicidality; regret rates for gender-affirming surgery in recent cohorts: 1–4%
Выдержка
“"The WPATH Standards of Care Version 8 evidence review confirms that gender-affirming medical and surgical interventions are associated with significant reductions in gender dysphoria, depression, anxiety, and suicidality in transgender and gender diverse adults. Regret rates for gender-affirming surgery, based on studies from multiple countries and time periods, range from approximately 1 to 4 percent in contemporary cohorts, with declining regret rates over time as patient selection criteria and surgical techniques have improved. Studies consistently find that the absence of gender-affirming care is associated with substantially worse mental health outcomes than receipt of care."
”
Данные источника:
2022-09-15
Дата обращения
2026-05-04
Расчёт
WPATH SOC v8 (Coleman et al. 2022). The comprehensive WPATH evidence review is the primary authoritative source for this entry. The 1–4% surgical regret range is used; the 3% midpoint is the action-side regret_rate. Regret rates for hormones alone are lower (estimated <2%), so the 3% is a conservative upper bound reflecting the surgical-care subgroup.
[2]Plastic and Reconstructive Surgery — Global Open — Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence
Проверено
Рецензируемая публикация
Systematic review and meta-analysis of 27 studies pooling 7,928 transgender patients who underwent gender-affirming surgery: pooled prevalence of regret 1% (95% CI <1%–2%)
Выдержка
“"A total of 27 studies, pooling 7928 transgender patients who underwent any type of GAS, were included. The pooled prevalence of regret after GAS was 1% (95% CI <1%–2%)."
”
Данные источника:
2021-03-19
Дата обращения
2026-05-04
Проверка
Выдержка независимо повторно загружена и подтверждена слово в слово по указанному источнику в ходе нашей проверки достоверности.
Расчёт
Bustos VP, Bustos SS, Mascaro A, et al. 2021, Plastic and Reconstructive Surgery Global Open 9(3):e3477 (DOI 10.1097/GOX.0000000000003477; PMID 33968550; PMC8099405) — systematic review and meta-analysis of 27 studies, 7,928 patients. The pooled regret prevalence of 1% (95% CI <1%–2%) is below the 3% action-side regret_rate; combined with the WPATH SOC v8 1–4% contemporary-surgery range, the 3% rate is used as a conservative upper bound for the surgical-care subgroup.
Источники: бездействие
Реестр утверждений
Каждое число ниже — это то, что сообщил источник, с дословной цитатой, на которую мы опирались, и тем, как мы пришли к нашей цифре. Нажмите на ссылку, чтобы проверить самостоятельно.
1/2 источников независимо дословно сверены с указанным источником
[1]Pediatrics — Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation
Проверено
Рецензируемая публикация
Cross-sectional survey of 20,619 transgender adults; among the 16.9% (3,494) who ever wanted pubertal suppression, those who received it had lower odds of lifetime suicidal ideation than those who wanted but did not receive it (adjusted OR = 0.3; 95% CI 0.2–0.6)
Выдержка
“"Using a cross-sectional survey of 20 619 transgender adults aged 18 to 36 years ... Of the sample, 16.9% reported that they ever wanted pubertal suppression as part of their gender-related care ... those who received treatment with pubertal suppression, when compared with those who wanted pubertal suppression but did not receive it, had lower odds of lifetime suicidal ideation (adjusted odds ratio = 0.3; 95% confidence interval = 0.2–0.6). ... There is a significant inverse association between treatment with pubertal suppression during adolescence and lifetime suicidal ideation among transgender adults who ever wanted this treatment."
”
Данные источника:
2020-02-01
Дата обращения
2026-05-04
Проверка
Выдержка независимо повторно загружена и подтверждена слово в слово по указанному источнику в ходе нашей проверки достоверности.
Расчёт
Turban et al. 2020, Pediatrics 145(2):e20191725 (DOI 10.1542/peds.2019-1725; PMID 31974216; PMC7073269). Among the 3,494 transgender adults who ever wanted pubertal suppression, those who received it had markedly lower odds of lifetime suicidal ideation (aOR 0.3; CI 0.2–0.6) than those who wanted it but could not access it. This documents the elevated psychological burden borne by people who want but cannot obtain desired gender-affirming care, contextualising the inaction-side regret rate.
[2]Advocates for Trans Equality (formerly National Center for Transgender Equality) — US Trans Survey
Авторитетный справочник
Largest US survey of transgender people (92,329 respondents): nearly all respondents who received gender-affirming care reported it made them more satisfied with their lives — gender-affirming hormone therapy 98%, transition-related surgeries 97%
Выдержка
“"Among those who accessed them, nearly all respondents said that gender-affirming hormone therapy (98%) or transition-related surgeries (97%) made them more satisfied with their lives."
”
Данные источника:
2024-02-08
Дата обращения
2026-05-04
Расчёт
2022 U.S. Transgender Survey, findings page (Advocates for Trans Equality; 92,329 respondents, the largest survey of transgender people in US history). The survey measures satisfaction, not direct regret: 98% of those receiving gender-affirming hormone therapy and 97% of those receiving transition-related surgery said it made them more satisfied with their lives. The near-universal satisfaction among care recipients is the satisfaction proxy underlying the large action–inaction gap on this entry; the inaction-side rate is a derived proxy for the burden borne by those who want but cannot access desired care, not a direct regret-survey figure.
Оговорки
This entry reflects the current state of the clinical evidence base for adults, as summarised in WPATH SOC v8 (2022) and the systematic literature. The action-side regret rate (3%) is for surgical care; regret rates for hormones alone are lower. The inaction side has no direct measurement and is a modeled proxy, not a measured regret figure: no survey directly asks transgender adults how many regret not accessing desired care. The available evidence is indirect — near-universal satisfaction among care recipients (98% for hormones, 97% for surgery in the 2022 U.S. Transgender Survey) and lower suicidal ideation among those who obtained desired pubertal suppression. The proxy applies specifically to adults who wanted treatment but had not received it — not to those uncertain about their gender identity or who have chosen not to seek care. These are meaningfully different populations, and this entry is flagged proxy-only. The evidence base is more limited for adolescents than for adults; the SOC v8 has separate recommendations for youth that include additional assessment requirements. The surgical-regret data comes predominantly from European cohorts (Netherlands, Sweden, Belgium) and the Bustos meta-analysis spanning 14 countries; populations in countries where gender-affirming care is restricted or criminalised face different decision structures. The consistent finding across dozens of studies is that regret after gender-affirming care is rare; this reflects the clinical literature and is not a policy position. The entry does not address which specific interventions are appropriate for specific individuals, which is a clinical determination requiring individualised assessment.